title: Interference of replication between hepatitis B and C viruses in patients infected with HIV.
abstract: The clinical and cellular interactions between hepatitis B virus (HBV) and hepatitis C virus (HCV) were investigated in patients co-infected with the human immunodeficiency virus (HIV). One hundred ninety-nine patients followed for 6 years were evaluated to compare the level of HBV DNA and HCV RNA in patients co-infected with HIV and HBV, and patients co-infected with HIV, HBV, and HCV. A full-length HBV genome and HCV JFH1 RNA were co-transfected into HuH-7.5.1 cells in vitro to examine the impact of co-infection and dependence on the HBV PreC mutant for replication interference. Before 2',3'-dideoxy-3'-thiacytidine (3TC)-based antiretroviral therapy (ART) was initiated, HBV DNA was found in 56/123 (45.4%) patients co-infected with HIV and HBV, and in 19/76 (25.0%) patients co-infected with HIV, HBV, and HCV. After 3TC-based ART was initiated, detectable HBV DNA decreased to 7/76 (9.2%) in patients co-infected with HIV, HBV, and HCV, but HCV RNA increased from 43/76 (56.6%) to 60/76 (78.9%) (P = 0.003). In vitro HBV and HCV co-infection led to decreased replication of both viruses. The primary factors that influenced the decreased replication were the order of the HBV and HCV infection and the HBV PreC mutation.
authors.affiliation: Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China.
authors.forename: Rong-Rong
authors.initials: RR
authors.lastname: Yang
authors.forename: Xien
authors.initials: X
authors.lastname: Gui
authors.forename: Xue-Yuan
authors.initials: XY
authors.lastname: Chen
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhu
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D018791:CD4 Lymphocyte Count; D045744:Cell Line, Tumor; D002681:China; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D006678:HIV / Q000235:genetics / Q000276:immunology; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics / Q000276:immunology / Q000821:virology; D016174:Hepacivirus / Q000235:genetics* / Q000276:immunology; D006509:Hepatitis B / Q000150:complications / Q000453:epidemiology / Q000235:genetics* / Q000276:immunology / Q000821:virology; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006515:Hepatitis B virus / Q000235:genetics* / Q000276:immunology; D006526:Hepatitis C / Q000150:complications / Q000453:epidemiology / Q000235:genetics* / Q000276:immunology / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage; D008137:Longitudinal Studies; D008297:Male; D009154:Mutation; D010957:Plasmids; D012367:RNA, Viral / Q000032:analysis; D012307:Risk Factors; D014162:Transfection; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000914:Antibodies, Viral; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D012367:RNA, Viral; D019259:Lamivudine